At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 215 enrolled
Drug / intervention
Brimo PS DDS® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
In Brief
A Phase 2 clinical trial evaluating Brimo PS DDS® and Sham for Patients Who Participated in an Intravitreal Brimo PS DDS® Study. Completed, enrolled 215 participants across 13 sites in 12 countries.
Detailed Summary
This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Czechia, France, Germany, India, Israel, Italy, Philippines, Portugal, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionFeb 2014
TodayJul 2026
First PostedMar 4, 2010
Enrollment StartFeb 1, 2010
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.3 years ago
Interventions
Brimo PS DDS®drug
Patients who received Brimo PS DDS® intravitreal implant in a previous study.
Shamother
Patients who recieved sham in a previous study.